Molecular structure of Obatoclax, CAS Number: 803712-67-6
Obatoclax (CAS 803712-67-6)
CAS Number:
803712-67-6
Molecular Weight:
317.38
Molecular Formula:
C20H19N3O
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Obatoclax (CAS 803712-67-6) References
- Obatoclax inhibits SARS-CoV-2 entry by altered endosomal acidification and impaired cathepsin and furin activity in vitro. | Mao, B., et al. 2022. Emerg Microbes Infect. 11: 483-497. PMID: 34989664
- Systems Drug Design for Muscle Invasive Bladder Cancer and Advanced Bladder Cancer by Genome-Wide Microarray Data and Deep Learning Method with Drug Design Specifications. | Su, PW. and Chen, BS. 2022. Int J Mol Sci. 23: PMID: 36430344
- In Silico Computational Studies of Bioactive Secondary Metabolites from Wedelia trilobata against Anti-Apoptotic B-Cell Lymphoma-2 (Bcl-2) Protein Associated with Cancer Cell Survival and Resistance. | Gowtham, HG., et al. 2023. Molecules. 28: PMID: 36838574
- Obatoclax Rescues FUS-ALS Phenotypes in iPSC-Derived Neurons by Inducing Autophagy. | Castillo Bautista, CM., et al. 2023. Cells. 12: PMID: 37759469
- Bcl-2 Antagonist Obatoclax Reactivates Latent HIV-1 via the NF-κB Pathway and Induces Latent Reservoir Cell Apoptosis in Latently Infected Cells. | Zhou, C., et al. 2023. ACS Infect Dis. 9: 2105-2118. PMID: 37796279
- Erratum: Targeting sphingosine kinase 2 suppresses cell growth and synergizes with BCL2/BCL-XL inhibitors through NOXA-mediated MCL1 degradation in cholangiocarcinoma. | Ding, X., et al. 2023. Am J Cancer Res. 13: 5746-5747. PMID: 38058829
- Nanomedicine for cancer targeted therapy with autophagy regulation. | He, K., et al. 2023. Front Immunol. 14: 1238827. PMID: 38239356
- An integrated framework for prognosis prediction and drug response modeling in colorectal liver metastasis drug discovery. | Zhou, X., et al. 2024. J Transl Med. 22: 321. PMID: 38555418
- Differential susceptibility of cells infected with defective and intact HIV proviruses to killing by obatoclax and other small molecules. | Kadiyala, GN., et al. 2024. AIDS. 38: 1281-1291. PMID: 38626436
- Therapeutic Implications of Targeting YY1 in Glioblastoma. | Navasardyan, I., et al. 2024. Cancers (Basel). 16: PMID: 38893192
Inhibitor of:
Baxα, Bcl-w, caspase-8, CRSP150_CRSP2, GOLT1B, and XAGE2B.Activator of:
Bax, Bcl-2, Bcl-B, and caspase-7.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Obatoclax, 10 mg | sc-507476 | 10 mg | $348.00 |